UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Low Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal Bleeding in a Meta-Analysis

Clinical gastroenterology and hepatology, 2011-09, Vol.9 (9), p.762-768.e6

2011

Volltextzugriff (PDF)

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL

PloS one, 2017-05, Vol.12 (5), p.e0173353-e0173353

2017

Volltextzugriff (PDF)

The psychosocial work environment is associated with risk of stroke at working age

Scandinavian journal of work, environment & health, 2017-07, Vol.43 (4), p.367-374

2017

Volltextzugriff (PDF)

WED 181 Switching early from oral DMT to fingolimod in RRMS patients

Journal of neurology, neurosurgery and psychiatry, 2018-10, Vol.89 (10), p.A24-A25

2018

Volltextzugriff (PDF)

Establishing pathological cut-offs for lateral ventricular volume expansion rates

NeuroImage clinical, 2018-01, Vol.18, p.494-501

2018

Volltextzugriff (PDF)

Methods and rationale of the DISCOVER CKD global observational study

Clinical Kidney Journal, 2021-06, Vol.14 (6), p.1570-1578

2021

Volltextzugriff (PDF)

Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis

The Lancet (British edition), 2021-08, Vol.398 (10300), p.577-578

2021

Volltextzugriff (PDF)

Estimated prevalence of secondary progressive multiple sclerosis in the USA and Europe: results from a systematic literature search (P2.380)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? – Authors’ reply

The Lancet (British edition), 2021-11, Vol.398 (10313), p.1801-1802

2021

Volltextzugriff (PDF)

Baseline Characteristics of Patients in the PANGAEA Study (P3.030)

Neurology, 2016-04, Vol.86 (16_supplement)

2016

Volltextzugriff (PDF)

Patient Reported Outcomes in Multiple Sclerosis: A Review of Literature (P2.134)

Neurology, 2016-04, Vol.86 (16_supplement)

2016

Volltextzugriff (PDF)

Persistence with multiple sclerosis disease-modifying therapies is highest when switching to fingolimod compared with other oral and injectable therapies: a retrospective US claims database analysis (P2.397)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

Multiple sclerosis in the real world: A systematic review of fingolimod as a case study

Autoimmunity reviews, 2017-04, Vol.16 (4), p.355-376

2017

Volltextzugriff (PDF)

Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations

Vaccine, 2022-09, Vol.40 (38), p.5585-5593

2022

Volltextzugriff (PDF)

Stroke patients' experiences of return to work

Disability and rehabilitation, 2006, Vol.28 (17), p.1051-1060

2006

Volltextzugriff (PDF)

Assessing ‘No Evidence of Disease Activity’ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study

CNS drugs, 2018-01, Vol.32 (1), p.75-84

2018

Volltextzugriff (PDF)

Real-World Use of Wearable Devices in a Large Multiple Sclerosis Cohort (P4.393)

Neurology, 2018-04, Vol.90 (15_supplement)

2018

Volltextzugriff (PDF)

Background rate estimations for thrombosis with thrombocytopaenia: challenges in evaluating rare safety signals following vaccination in real time during a pandemic

BMJ open, 2023-01, Vol.13 (1), p.e063645

2023

Volltextzugriff (PDF)

Characteristics, Symptom Severity, and Experiences of Patients Reporting Chronic Kidney Disease in the PatientsLikeMe Online Health Community: Retrospective and Qualitative Study

Journal of medical Internet research, 2020-07, Vol.22 (7), p.e18548-e18548

2020

Volltextzugriff (PDF)

Multiple Sclerosis Care Optimization Tool (MS-COT): A Clinical application prototype to predict future disease activity (P1.368)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study

Diabetes research and clinical practice, 2022-03, Vol.185, p.109218-109218, Article 109218

2022

Volltextzugriff (PDF)

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA

Neurotherapeutics, 2018-01, Vol.15 (1), p.190-199

2018

Volltextzugriff (PDF)

Predicting Disease Activity for Patients with Relapsing Remitting Multiple Sclerosis Using Electronic Medical Records (P1.395)

Neurology, 2016-04, Vol.86 (16_supplement)

2016

Volltextzugriff (PDF)

Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study

Diabetes research and clinical practice, 2021-10, Vol.180, p.108974-108974, Article 108974

2021

Volltextzugriff (PDF)

Feasibility of brain atrophy measurement in clinical routine: Results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in RRMS patients (S12.004)

Neurology, 2017-04, Vol.88 (16_supplement)

2017

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(33)

Publikationsform

Artikel
(46)

Sprache

Englisch
(45)
Schwedisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(25)
Humans
(21)
Female
(17)
Male
(16)
Middle Aged
(16)
Adult
(12)
Multiple Sclerosis
(10)
Aged
(8)
Neurosciences & Neurology
(7)
Patients
(7)
Social Sciences
(7)
Fingolimod
(6)
Medicine
(6)
Clinical Neurology
(5)
Fingolimod Hydrochloride - Therapeutic Use
(5)
Magnetic Resonance Imaging
(5)
Medicin Och Hälsovetenskap
(5)
Neuroimaging
(5)
Neurology
(5)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Low Doses of Acetylsalicylic Acid Increase Risk of Gastrointestinal Bleeding in a Meta-Analysis

Two studies in one: A propensity-score-matched comparison of fingolimod versus interferons and glatiramer acetate using real-world data from the independent German studies, PANGAEA and PEARL

The psychosocial work environment is associated with risk of stroke at working age

WED 181 Switching early from oral DMT to fingolimod in RRMS patients

Establishing pathological cut-offs for lateral ventricular volume expansion rates

Methods and rationale of the DISCOVER CKD global observational study

Very rare thrombosis with thrombocytopenia after second AZD1222 dose: a global safety database analysis

Estimated prevalence of secondary progressive multiple sclerosis in the USA and Europe: results from a systematic literature search (P2.380)

Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? – Authors’ reply

Baseline Characteristics of Patients in the PANGAEA Study (P3.030)

Patient Reported Outcomes in Multiple Sclerosis: A Review of Literature (P2.134)

Persistence with multiple sclerosis disease-modifying therapies is highest when switching to fingolimod compared with other oral and injectable therapies: a retrospective US claims database analysis (P2.397)

Multiple sclerosis in the real world: A systematic review of fingolimod as a case study

Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations

Stroke patients' experiences of return to work

Assessing ‘No Evidence of Disease Activity’ Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study

Real-World Use of Wearable Devices in a Large Multiple Sclerosis Cohort (P4.393)

Background rate estimations for thrombosis with thrombocytopaenia: challenges in evaluating rare safety signals following vaccination in real time during a pandemic

Characteristics, Symptom Severity, and Experiences of Patients Reporting Chronic Kidney Disease in the PatientsLikeMe Online Health Community: Retrospective and Qualitative Study

Multiple Sclerosis Care Optimization Tool (MS-COT): A Clinical application prototype to predict future disease activity (P1.368)

Quality of life in people with type 2 diabetes in the 3 years following initiation of second-line therapy: The DISCOVER study

Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit–Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA

Predicting Disease Activity for Patients with Relapsing Remitting Multiple Sclerosis Using Electronic Medical Records (P1.395)

Health-related quality of life in patients with type 2 diabetes initiating a second-line glucose-lowering therapy: The DISCOVER study

Feasibility of brain atrophy measurement in clinical routine: Results from MS-MRIUS, a longitudinal observational, multicenter real-world outcome study in RRMS patients (S12.004)

Suchergebnisse filtern